PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33565716-0	2021	Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.	Oxaliplatin	32-43	urothelial cancer associated 1	Homo sapiens	12-16	
33565716-10	2021	Besides, depletion of UCA1 triggered more dramatic regression of HepG2 xenografts than that of HepG2/OXA xenografts with OXA treatment and impaired the p-AKT and p-mTOR levels in vivo.	Oxaliplatin	101-104	urothelial cancer associated 1	Homo sapiens	22-26	
33565716-11	2021	In conclusion, our findings provide the evidence that UCA1 may contribute to OXA resistance via miR-138-5p-mediated AK /mTOR activation, suggesting that UCA1 is a potential therapeutic target for HCC.	Oxaliplatin	77-80	urothelial cancer associated 1	Homo sapiens	54-58	
33565716-11	2021	In conclusion, our findings provide the evidence that UCA1 may contribute to OXA resistance via miR-138-5p-mediated AK /mTOR activation, suggesting that UCA1 is a potential therapeutic target for HCC.	Oxaliplatin	77-80	urothelial cancer associated 1	Homo sapiens	153-157	
31432188-0	2019	The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.	Oxaliplatin	81-92	urothelial cancer associated 1	Homo sapiens	34-38